Login to Your Account

Rough road for BACE inhibitors

Vitae Pharmaceuticals Inc. shares (NASDAQ:VTAE) picked up slightly Friday, gaining 46 cents, to close at $9.11, after soaring as high as $12.25, on positive top-line data from a phase I study in which an early stage experimental Alzheimer's disease therapy it co-developed with Boehringer Ingelheim GmbH reduced amyloid beta levels in cerebral spinal fluid (CSF) by more than 80 percent. more »

Our Habitat for All Things Science
For Ebola victory, scientific advances could help with nonscientific challenges

From a purely scientific standpoint, the news about the Ebola outbreak has been encouraging. New genomic technologies enable unprecedented surveillance of the virus. There are drugs and vaccines in clinical trials. And in response to the urgency of the crisis, both drugmakers and regulatory agencies are making efforts to expedite the process of getting weapons against Ebola through the regulatory process and into the field, where they are needed. (See BioWorld Today, Oct. 22, 2014.)



Partners in Focus